IXICO plc Additional Director's Dealings

February 5, 2016

5 February 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 4 February 2016 that, on the same day, Professor Derek Hill, Chief Executive of the Company, purchased 10,000 Ordinary Shares of 1p each in IXICO at a price of 33.68p pence per Ordinary Share.

As a consequence of this share purchase, Professor Derek Hill is beneficially interested in 487,169 Ordinary Shares representing 1.84% of the Company's issued share capital.

Click here for Shareholder Information.


Derek Hill, CEO
Susan Lowther, CFO

+44 20 3763 7499

Peel Hunt LLP (Nominated Adviser and Broker)
James Steel / Oliver Jackson

+44 20 7418 8900

Daniel Stewart & Company (Joint Broker)
Martin Lampshire / David Coffman

+44 207 776 6550

FTI Consulting Limited (Investor Relations)
Simon Conway / Mo Noonan / Matthew Moss

+44 20 3727 1000
Notes to Editors
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.